Corbus Pharmaceuticals Holdings, Inc. 8-K

What Happened
Corbus Pharmaceuticals Holdings, Inc. filed an 8-K (dated April 7, 2026) reporting two material items: (1) Dominic Smethurst, the company’s Chief Medical Officer, notified the company on April 1, 2026 that he will resign effective June 30, 2026; and (2) the company announced broad alignment with the U.S. Food and Drug Administration (FDA) on the registrational path for CRB-701, its next-generation, highly stable Nectin-4 targeting antibody‑drug conjugate (ADC), in second-line head and neck squamous cell carcinoma (HNSCC) and cervical cancer. A press release describing the FDA discussions was furnished as Exhibit 99.1.

Key Details

• Date of filings/announcements: CMO resignation notice on April 1, 2026; press release and 8-K filed April 7, 2026.
• CMO departure: Dominic Smethurst to resign effective June 30, 2026.
• CRB-701 registrational design (FDA-aligned):
  • HNSCC: single randomized controlled study vs. physician’s choice chemotherapy; potential accelerated approval using objective response rate (ORR) as primary endpoint; potential full approval based on overall survival (OS).
  • Cervical cancer: single randomized controlled study vs. physician’s choice chemotherapy or Tivdak®; potential accelerated approval using ORR as primary endpoint; potential full approval based on OS.
• Next steps: continued interactions with the FDA to finalize study protocols and statistical analysis plans.

Why It Matters
The 8-K reports a leadership change that investors should note (CMO resignation effective June 30, 2026). Separately, Corbus disclosed that it has reached broad agreement with the FDA on the clinical development plan for CRB-701 in two second-line indications, including the use of ORR as a potential basis for accelerated approval and OS for full approval. Those agreed design elements clarify regulatory expectations and the company’s planned path for pivotal studies, which are key milestones for the drug’s development timeline. The filing does not include financial results or timelines for study starts; the company plans further FDA interactions to finalize protocols.